KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $428.0 million.

  • Teva Pharmaceutical Industries' Income towards Parent Company rose 160.11% to $428.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.0 million, marking a year-over-year increase of 116.01%. This contributed to the annual value of -$2.0 billion for FY2024, which is 59.01% down from last year.
  • Teva Pharmaceutical Industries' Income towards Parent Company amounted to $428.0 million in Q3 2025, which was up 56.20% from $274.0 million recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Income towards Parent Company peaked at $428.0 million during Q3 2025, and registered a low of -$2.4 billion during Q4 2023.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Income towards Parent Company value was -$506.0 million (recorded in 2023), while the average stood at -$581.3 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 111.53% in 2022, then spiked by 160.11% in 2025.
  • Teva Pharmaceutical Industries' Income towards Parent Company (Quarterly) stood at -$1.1 billion in 2021, then slumped by 90.51% to -$2.1 billion in 2022, then declined by 13.53% to -$2.4 billion in 2023, then skyrocketed by 88.33% to -$282.0 million in 2024, then spiked by 160.11% to $428.0 million in 2025.
  • Its last three reported values are $428.0 million in Q3 2025, $274.0 million for Q2 2025, and $213.0 million during Q1 2025.